Invasive Candida Infection after Upper Gastrointestinal Tract Surgery for Gastric Cancer
Table 1
Patient demographics, underlying conditions, nutritional data, length of ICU, and hospital stay (Group 1: no infectious complications; Group 2: patients who developed documented intra-abdominal infection).
Group 1 ()
Group 2 ()
valu
Age, years (mean ± SD)
62.67 ± 9.1
72.38 ± 14.
0.002
Weight, Kg (mean ± SD)
72.78 ± 12.75
72.85 ± 13.7
0.7
Gender (male)
48/100 (48%)
24/49 (49%)
0.5
Type of upper surgery
Total gastrectomy
56/100 (56%)
26/49 (53.1%)
0.8
Partial gastrectomy
44/100 (44%)
23/49 (46.9%)
0.9
Underlying condition (%)
Without chronic disease
36/100 (36%)
15/49 (30.6%)
0.6
Diabetes mellitus
10/100 (10%)
18/49
0.04
31/100 (31%)
14/49 (35.8%)
0.5
Hypertension
23/100 (23%)
1/49
<0.001
Chronic therapy (%)
Without chronic therapy
36/100 (36%)
15/49 (30.6%)
0.46
Statins
20/100 (20%)
16/49 (32.6%)
0.04
44/100 (44%)
18/49 (36.7%)
0.29
TPN (, %
27/100 (27%)
36/49 (73.5%)
<0.001
Length of stay (day ± SD)
ICU length of (day, mean ± SD)
1.25 ± 0.67
12.04 ± 1.49
<0.001
Hospital length of stay (day, mean ± SD)
10.84 ± 4.8
32.2 ± 2.4
<0.001
is considered to be significant; GIT: gastrointestinal tract; CIHD: chronic ischemic heart disease; ACE: angiotensin-converting enzyme. Percent total parenteral nutrition after oncologic upper GIT surgery. Some of the patients from Group 1 were also hospitalized in the GICU for a postoperative observation period.
